(1S,2S)-2-(4-Bromophenyl)cyclopropanecarboxylic acid, 97%, 5g

(E)-N-[(2-fluorophenyl)methylidene]hydroxylamine, 98%, 250mg

C8 alkyne dCTP, min. 95%, 100 mM in water, 10 µl, plastic package.

Benzyl L-(+)-Mandelate>98.0%(GC)25g

3,4-Diiodofluorobenzene, 99.0%, 100g

1-(2-Phenylpropan-2-yl)piperidine, 95.0%, 1g

6-[4-(3-Chlorophenyl)piperazin-1-yl]-3-cyclohexyl-1,2,3,4-tetrahydropyrimidine-2,4-dione, 98.0%, 5mg

3-Chloromethyl-5-thiophen-2-yl-isoxazole, 95.0%, 1g

3-Undecanol>94.0%(GC)5mL

4-(Benzyloxy)-2-methoxybenzaldehyde, 97.0%, 1g

1,3-Dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione, 98%, 5g

N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)quinazolin-4-amine, 98+%, 1g

1-(2-Aminoethyl)azetidin-3-ol, 98%, 250mg